| 前收市價 | 1.3700 |
| 開市 | 1.3700 |
| 買盤 | 0.0000 |
| 賣出價 | 0.0000 |
| 拍板 | 118.00 |
| 到期日 | 2024-06-07 |
| 今日波幅 | 1.3700 - 1.3700 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
BenzingaSummit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
鉅亨網Merck砸30億美元收購眼科藥物開發商EyeBio
美國製藥大廠 Merck(默沙東 / 默克) 周三 (29 日) 同意以高達 30 億美元的價格收購民間生物技術公司 EyeBio，這是 Merck 為促進未來營運成長而進行一連串交易中的最新一筆。這筆交易將於今年第三季完成。
ReutersMerck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
